The Lockheed Martin-backed PCB manufacturing software provider’s reverse takeover deal will involve it listing on the Nasdaq Stock Market.

The Barracuda Networks-backed expense management software provider has filed to go public having disclosed less than $28m in funding.

The Duchenne muscular dystrophy drug developer's initial public offering could prove an exit ramp for Roche and Merck & Co.

The Lundbeck, Chiesi Group and Li-Cor Biosciences-backed eye and bladder cancer therapeutics developer has filed to go public on Nasdaq in an offering with a $100m placeholder target.

SoftBank is set to achieve an exit as the warehousing robotics technology developer prepares to go public in Oslo on October 20.

Eli Lilly, Taikang and Tencent are in line to exit the diabetes equipment maker, which has filed to go public in Hong Kong next week.

Quanta Services is contributing to a PIPE deal for the IAC-backed internet service provider’s reverse takeover valuing the combined business at $1.66bn.

Bayer, Pfizer and Ipsen-backed cancer therapeutics developer Pyxis Oncology priced its shares at the top of its range.

The dental technology developer’s proposed listing on the New York Stock Exchange would mark an exit for Henry Crown and Company.

The Ariad Pharmaceuticals-backed cancer therapeutics developer floated at the top of its range following $120m in venture funding.